Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.75 USD
Change Today -0.05 / -6.25%
Volume 1.2M
ONCY On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONCY) Snapshot

Open
$0.78
Previous Close
$0.80
Day High
$0.78
Day Low
$0.70
52 Week High
07/9/14 - $1.69
52 Week Low
10/10/14 - $0.40
Market Cap
75.5M
Average Volume 10 Days
1.8M
EPS TTM
--
Shares Outstanding
100.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONCY)

oncolytics biotech inc (ONCY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONCY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONCY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

oncolytics biotech inc (ONCY) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: C$530.0K
Chief Financial Officer
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: C$149.8K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONCY) Key Developments

Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas

Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of malignant glioma. The company applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies including gliomas, REOLYSIN has been shown to infect a variety of brain tumors when delivered intravenously. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Gastric Cancer

Oncolytics Biotech® Inc. announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN® for the treatment of gastric cancer. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Oncolytics Biotech Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:20 PM

Oncolytics Biotech Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Bradley G. Thompson, Executive Chairman, Chief Executive Officer, President and Member of Compensation Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $0.75 USD -0.05

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies
 

Industry Analysis

ONCY

Industry Average

Valuation ONCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.